cagrisema semaglutide Did Not Meet Primary End Point of Noninferiority to Tirzepatide Efficacy and safety of once-weekly

[DOI] [PubMed] [Google Scholar] 3.Kooij J., Bijlenga D., Salerno L., Jaeschke R., Bitter I., Balzs J., Thome J., Dom G., Kasper S., Filipe C.N., et al

What the clinical trial evidence shows Mounjaro (tirzepatide) ~22.5% average body weight lost at 72 weeks ( SURMOUNT-1, 15mg) Wegovy (semaglutide) ~14.9% average body weight lost at 68 weeks ( STEP-1 , 2.4mg) Saxenda / Nevolat (liraglutide) ~5-8% average body weight lost at 56 weeks ( SCALE trial ) For context, prior to GLP-1 medications, the most effective non-surgical weight loss intervention available was a combination of intensive lifestyle modification and Orlistat , which typically produces 5 to 8% weight loss

However, tetracycline, minocycline, dapsone, and topical corticosteroids are also mentioned as treatment options (234, 235, 237)

While its true that some individuals experience weight regain after coming off GLP-1 therapy, its not inevitable

This is a life-threatening emergency

While shortages of certain formulations of Adderall have been resolved, other formulations remain in shortage, according to the FDA